Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Researchers at Hiroshima University have analyzed the molecular findings of almost 160 pediatric liver cancer cases and discovered molecular markers that should help to understand and treat the considerable variation in prognoses.
A team of researchers recently postulated a genetic classifier with the ability to predict the sensitivity of neoadjuvant chemotherapy for breast cancer in the area of tumor molecular markers.
A research team led by Prof. DAI Haiming from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences recently announced the constitutive BAK/MCL1 complexes could predict chemotherapy drugs sensitivity of ovarian cancer. The result has been published on Cell death & disease.
Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at bay from the lungs.
Most of the cells in our bodies – be they bone, muscle or pancreas cells – are locked into the right place with the help of tiny anchors (called 'focal adhesions').
In a new study, researchers have introduced DSER, a technique for identifying molecular targets for enhanced therapy in prostate cancer.
Researchers from Northwestern Medicine unearthed the epigenetic processes involved in the regulation of multiple oncogenes in glioma cells.
New research published today in JAMA Oncology reports how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination.
Cell growth requires new proteins and the same applies to cancer cells. Scientists analyzed the protein eIF4A3 and its role in the growth of cancer cells.
Cancer cells sometimes develop resistance to the cytotoxic drugs used in chemotherapy. Figuring out why the treatment isn't working and why it may even defeat its own purpose is therefore important to understand.
Scientists and faculty of Vanderbilt University are in search of the “Achilles’ heel” of cancer cells that survive initial chemotherapy.
Researchers have used sophisticated imaging technology to offer unmatched insights into the BRCA1-BARD1 protein complex.
Cell-free DNA (cfDNA) shed into the blood was discovered in the late 1940s but with rapid advances in genomics and computational analytics in just the past few years, researchers at Georgetown Lombardi Comprehensive Cancer Center now believe that studying tags, or modifications to this type of DNA, may lead to a better understanding of how to assess, and possibly modulate, treatment approaches for cancer and other diseases.
A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
In the evolving field of cancer biology and treatment, innovations in organ-on-a-chip microdevices allow researchers to discover more about the disease outside the human body.
A new study reports the use of single-cell, force spectroscopy methods to probe biophysical and biomechanical kinetics of cancer cells.
Oncotarget published "Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy" which reported that by exploiting single-cell, force spectroscopy methods, the authors probed biophysical and biomechanical kinetics of brain, breast, prostate, and pancreatic cancer cells with standard chemotherapeutic drugs in normoxia and hypoxia over 12-24 hours.
Wake Forest researchers and clinicians are using patient-specific tumor 'organoid' models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.
Most of the tests that doctors use to diagnose cancer -- such as mammography, colonoscopy, and CT scans -- are based on imaging. More recently, researchers have also developed molecular diagnostics that can detect specific cancer-associated molecules that circulate in bodily fluids like blood or urine.
In a recent study, researchers investigated how natural killer cells target breast cancer using the body's own immune system.